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Condusion: These results demonstrate that differences between the total
antimicrobial effect with and without ARB over the potentially therapeutic
AUC/MIC range are almost negligible.
IMoP263I Comparative pharmacodynamics of gemifloxacin
(GEM) and levofloxadn (LEV) with Staphylococcus aureus and
Escherichia coil In an in vitro dynamic model
I. lubenko!, S. Vostrov\ A. Firsov\ S. Zinner2
lCentrefor Science & Technology LekBioTech, Moscow, Russian Fedl'ralion;
2Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, United
States
Objectives: To compare the pharmacodynamics ofGEM and lEV in terms
of the AUCfMIC- and dose (D)-response relationships.
Methods: Two clinical isolates of S. aureus and one of E. coli (MICs 0.01,
0.04 and 0.1 J.lg/ml ofGEM and 0.25, 0.6 and 0.2 J'g/ml ofLEV, respectively)
were exposed to monoexponentially decreasing concentrations of GEM
(Tl/2 = 7.4 h) or lEV (Tl/2 = 6.8 h). Eight-fold ranges ofthe AUCfMIC
ratio. 58-466 and 116-932 (J.lg x h/ml)/(/lg/ml), were simulated with GEM
and lEV, respectively. The total AME was expressed by the IE parameter.
Results: linear relationships established between IE and log AUCfMIC of
GEM or lEV were strain-, species- and quinolone-independent (,2 = 0.99 in
each case). The strain-independent patterns of these relationships allowed
extrapolation of the data obtained with specific organisms to hypothetical
strains ofS. aureus and E. coli with MICs = MICSOs (0.04 and 0.03 J.lg/ml of
GEM and 0.7 and 0.03 J.lg/ml oflEV, respectively). Based on the respective
D-response relationships, the equiefficient 24-h Ds of GEM and lEV were
predicted. With E. coli, usual clinical Ds of both GEM (320 mg) and LEV
(500 mg) are able to provide acceptable IEs. With S. aureus, a 320 mg D of
GEM was equiefficient to a much greater D of lEV (3000 mg) that is far in
excess of what may be given clinically.
Condusions: This analysis might be useful to predict in vitro the antimi-
crobial potentials of other newly developed fluoroquinolones.
IMoP264IEffects of grepafloxadn in a murine limb bud
culture
Mehdi Shakibaei, Irmela Baumann-Wilschke!, Marcus RUcker!, Ralf
Stahlmann!
lnstitutjr,r Anatomie; Ilnstitutfr<r Klinische Pharmakologie und Toxikologie,
UKBF, Freie Univl'rSitiit Bl'rlin, Germany
Objectives: To study the affinity of grepaftoxacin to calcium and magne-
sium and to investigate the effects of the quinolone on growth and
differentiation of limb buds from 12-day old mouse embryos in vitro.
Methods: Affinity of grepaftoxacin to divalent cations was determined by
measuring the fluorescence at various concentrations of Mg2 + or Ca2 +.
The drug was added to the culture medium oflimb buds (culture period: 6
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ITu027I Emergence of vancomydn intermediate
Staphylococcus aureus (VISA) in patients with methidllin
resistant S. aureus (MRSA) infection in a Belgian hospital
O. Denis, C. Nonhoff, B. Byl, C. Knoop. M.J. Struelens
Microbiology, Infectious Disease and Pneumology Dpt, Hopital Erasme,
Universite Libre de Bruxelles. Brussels. Belgium
objectives: To detect S. aureus with intermediate susceptibility (VISA) to
vancomycin and to determine its clinical and epidemiological impact in a
860-bed teaching hospital in 1999.
Methods and: results: In 1999, all clinical S. aureus isolates were screened for
decreased susceptibility by vancomycin (6 J.tg/ml) agar screen method
followed by MICs determination (broth microdilution, E-test with 0.5
days) at concentrations between 10 and 100 mgt!. Explants were evaluated
under a dissecting microscope and by electron microscopy.
Results: Grepafloxacin showed a pronounced affinity to calcium as deter-
miend with the fluorescence assay which was higher than the affinities ofsix
other fluoroquinolones tested before (Forster et al. Arch. Toxico!. 72: 411,
1998); affmity to magnesium was similar to that of ciprofloxacin. Grepa-
Aoxacin affecred the growth of the limb buds at concentrations of30 mgfl
and higher; effects were not enhanced when limbs were cultured in a
magnesium-deficient medium. With lower concentrations (10 mgfl) char-
acteristic changes were seen electron microsopically (e.g. detachment ofcell
membrane from matrix, matrixfree periciellular areas, swelling of cell
organelles), higher concentrations caused a completely degraded matrix
and necrotic chondrocytes.
Conclusions: Effects of grepafloxacin in this limb bud assay were more
pronounced than those observed with other quinolones; this might be
related to the rather high affinity of the fluoroquinolone to calcium.
IMoP265] Rlbavlrln treatment of hepatitis C In end stage
renal disease
A. Bruchfeldt, R. Schvarcz2.J. Andersson2,J. -0. Svensson', L. Stahle'
'Renal Medicine; 2Infettious Diseases; JC/inical Pharmacology, Huddinge,
Sweden Hospital; Karolinska Institute
Objective: To investigate the safety ofribavirin treatment in end stage renal
disease (ESRD), since hepatitis C is a prevalent disease in this patient
category. It has been stated repeatedly that ribavirin is contraindicated in
ESRD due to fear of side-effeets. Having recently developed a high-
performance liquid chromatography (HPlC) method to measure ribavirin,
we intended to investigate if close ribavirin drug monitoring and intensive
control ofanemia was safe during interferon-alfa 2b and ribavirin therapy in
ESRD.
Method: Ribavirin was analysed by HPLC after selective solid phase
extraction. Virological, biochemical and clinical status was monitored. 5
patients, 4 on hemodialysis and 1 on peritoneal dialysis, were recruited to the
study.
Results: Ribavirin through levels were initially monitored weekly and
concentrations about 10-12 uM were achieved. The average final dose of
ribavirin was in the range of170-300 mg/day. The peritoneal dialysis patient
did not differ from a pharmacokinetic point of view.
Ribavirin induced anemia was handled by high doses oferythropoeitin. 3
patients completed the intended 28 weeks of treatment (4 weeks of inter-
feron monotherapy followed by 24 weeks of combination therapy). 1
patient had severe interferon related side-effects and therapy was terminated.
1 patient died after 14 weeks due to heart failure associated with severe
cardiac hypertrophy, which was not considered to be treatment related.
Conclusion: The results indicate that ESRD patients can be treated with
ribavirin under strictly conttolled conditions, but it requires dose reduction,
monitoring of ribavirin concentrations as well as high-dose erythropoetin
treatment to avoid severe anemia.
McF inoculum on Mueller Hinton agar and 2 McF inoculum on Brain Heart
Infusion agar) and population analysis. VISA were detected in three patients
colonized with MRSA endemic genotype 1 (sputum from a cystic fibrosis
patient) and genotype 4 (sputum and decubitus ulcer in two ICU patients).
MICs of vancomycin ranged from 8-16 /lg/ml (broth), 4-8 p,g/ml (E-tcst
10':" inoculum) to 1~-32 ~/ml ~-test high inoculum). Resistant subpopu-
lations were seen With 10 -10 frequCDctCS at 8 J.tg/ml. All patients had
received multiple courses of vancomycin for therapy of MRSA lung and
blood infection prior to VISA detection. No secondary spread ofVISA was
found among contact patients or staff. In the CF patient with MRSA/VISA
associated acute exacerbation ofchronic bronchitis, therapy with continuous
vancomycin infusion (20-35 p,g/ml serum) followed with oral minocyclin-
fucidic acid was effective.
Conclusion: In this Belgian hospital, VISA emerged sporadically in patients
under prolonged vancomycin therapy for persistent MRSA infections
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caused by endemic clones. In one case, VISA infection appeared to respond
to high doses vancomycin associated with other antimicrobials.
ITu02SI Role of Mycoplasma pneumoniae and Chlamydia
pneumoniae in children with acute pharyngitis
S. Esposito, F. Blasi!, C. Arosio·, N. Morelli!, 1. Fioravanti, M. Betti l , R.
Droghetti, S. Bosis, 1. AllegraI, N. Principi
Paediatr Dept IV, L. Sacco Hosp, Univ. Milan; 'Inst Resp Dis,IRCCS
Maggiore Hosp, Univ Milan, Italy
In order to investigate the role of Mycoplasma pneumoniae (Mpn) and
Chlamydia pneumoniae (Cpn) in the aetiology of acute pharyngitis, the
incidence of Mpn and Cpn infection was studied in ISO children aged 0-
14 years (87 males, median age 4 yrs) presenting with an acute episode of
pharyngitis and 137 age- and sex-matched controls without any evidence of
acute respiratory infection. Serum samples and nasopharyngeal aspirates
were obtained on admission and after 4-6 weeks in all the children. Each of
the sera was tested for IgM and IgG antibodies to Mpn (enzyme-linked
immunosorbent assay, Pantec, Italy) and for IgM,lgA and IgG antibodies to
Cpn microimmunoftuorescence, Labsystems, Finland). On nasopharyngeal
aspirates, polymerase chain reaction for Mpn and Cp" detection was
performed as previously described. The Table shows the distribution of
children with acute Mpn and Cpn infection according to age group and
clinical diagnosis.
Age group Mpn infection (%) Cpn infection (%)
Patients Controls Patients Controls
0-2 yrs 5{39 (12.8) 1{29 (3.5) 4{39 (10.3) 0{29
3-4 yrs 5{55 (9.1) 1{44 (2.3) 5{55 (9.1) 1{44 (2.3)
2':5yrs 12{56 (21.4) 4{64 (6.2) 9{56 (16.1) 1{64 (1.6)
At enrollment, no significant difference in clinical signs, symptoms and
laboratory data was observed among children with or without infection due
to atypical bacteria. Our data suggest a remarkable role for Mpn and Cpn in
children with acute pharyngitis and confirm the low prevalence ofMpn and
Cpn carriage among healthy children.
ITu029IEpidemic of MRSA among intravenous drug users
F. Fleisch, R. Zbinden, C. Vanoli, C. Agosti, T. Bar, C. Ruef
University Hospital and University ofZurich, Switzerland
Background: The prevalence ofmethicillin-resistant Staphylococcus aureus
(MRSA) in Switzerland is low. A relatively high number of intravenous
drug users (IDUs) in the Zurich area has multiple contacts with various
medical facilities. During the early '90s, MRSA was isolated sporadically
from IOU's.
Objectives: To describe an outbreak of MRSA among IDUs and to
determine the prevalence of MRSA carriership and/or infections in IDUs.
Methods: Prospective registration of MRSA cases in the Zurich area,
genotyping of all MRSA isolates, retrospective review of medical records,
screening of IDUs (nose swabs) in several outpatient facilities (i.e. drug
dispensaries) .
Results: Berween 5/95-12/99 we registered 34 IDUs with MRSA infection
and/or colonization. MRSA was detected sporadically among IOUs during
the years '95 to '97, whereas a marked increase was noted during '98 and '99.
Infections requiring hospitalization were found in 31 of 34 patients (12
wound/soft tissue infections, 7 pneumonias, 7 cases of endocarditis, 2
oste:omyelitis, 2 septic arthritis, 1 ulcerative tonsillitis). Of the 34 patients,
16 (47%) were infected with HIV and showed various degrees of cellular
immunodeficiency. All 34 isolates showed identical banding patterns by
PFGE. MRSA carriage rate was 10.3% in IDUs with a wide variation
berween the different facilities ranging from 0% to 28.6%. Significant risk
factors for MRSA carriage were drug consumption in the group, disability
and prior hospitalization in a hospice.
Conclusion: MRSA is endemic in IOUs in Zurich. The increase in the
incidence of MRSA resulted from spread of a single clone. This observed
clone caused major morbidity :md was responsible for a lethal outcome in 2
patients.
!Tu0301 Evaluation of fluoroquinolone activity among
European isolates of Streptocoeeus pneumoniae
M. E. Jonesl , A. M. Staples2, I. Critchlel, D. F. Sahm2
'MRL Pharmaceutical Services, Utrecht, Netherlands; 2Hemdon, Virginia,
United States
ObJectIves: Increasing resistance among S. pneumoniae is :m important
clinical issue. New ftuoroquinolones (FQs) are now available for use against
S. pneumoniae, including moxifloxacin (MXF). Although these agents
demonstrate high activity, the potential for resistance exists and must be
monitored.
Methods: During 1998, we collected 900 S. pneumoniae isolates from 30 sites
(five European countries). MICs for penicillin, amoxicillin/clavulanate,
cefuroxime, erythromycin, trovafioxacin, grepaftoxacin, levofioxacin, spar-
f10xacin and MXF were determined according to NCCLS recommenda-
tions.
Results: Resistance among S. pneumoniae to FQs was rare (5/9<XJ; 0.2%). For
MXF and trovafloxacin, the MIC90s were 0.121'8/ml; > 90% of isolates
had MICs that were ~3 dilutions below the FDA or NCCLS susceptible
breakpoint (1 ISg/ml), 99% of isolates had MICs ~ 2 dilutions below the
breakpoint. The remaining FQs showed 3-11 % ofisolates ~3 dilutions and
30-84% ~ 2 dilutions, respectively, below the breakpoint. Only five isolates
were non-susceptible to one or more FQs. Of these, three remained
susceptible to MXF and four remained susceptible to trovaftoxacin. All
five were non-susceptible to grepaftoxacin, sparlloxacin and levoftoxacin,
and carried GyrA alterations at Ser8I. ParC Ser79-+Phe contributed to the
high-level FQ resistance detected in the strain that was not susceptible to :my
of the FQs. PFGE showed the five resistant isolates to be non-clonal.
Conclusions: While FQ resist:mce among S. pneumoniae is rare, the capacity
to develop resistance warrants monitoring. In contrast to other studies, FQ
resistance was not linked with penicillin resistance in this study.
ITuo31[ A Family duster of Streptococcal Toxic Shock
Syndrome in Children: Clinical implication and epidemiologic
investigation
Y. C. Huang, P. R. Hsueh!, T. Y. Lin, D. C. Van, S. H. Hsia
Department ofPediatric Medicine, Chang Gung Children's Hospital;
'Department ofLaboratory Medicine, National Taiwan University Hospital,
Kweishan, Taoyuan, Taiwan
Background: Most invasive group A Streptococcal (GAS) disease occurred
sporadically_Rcpor" of falnily du.ten of these infections are SCllnty and
most invasive diseases occur in adults. We describe a family cluster of
streptococcal toxic shock syndrome (STSS) involving three children :md the
results of a epidemiologic investigation.
PatIents and Methods: During a 16-day period three children in a family
developed STSS with an interval of 10 and 6 days, respectively berween the
onset ofdiseases. Cases 2 and 3 had GAS isolated from blood culture. Case 2
was fatal. Pharyngeal cultures survey of the family members and school-
children were conducted. Antibiogram, serotyping, detection of exotoxin
genes and random amplified polymorphic DNA patterns of the disease
strains and survey strains were examined.
Results: One (7%) (the sister of index case) of 15 family members sampled
:md 7 (5.6%) of 125 schoolchildren sampled had GAS isolated from
pharyngeal cultures. Of these 10 strains examined, rwo isolates from the
patients, one from the sister ofindex case and two from the classmates ofcase
2 (fatal case) had an identical pattern of both genotype and phenotype.
Conclusion: We describe a family cluster ofSTSS caused by a unique clone
and provide an additional data to support antimicrobial prophylaxis to
prevent subsequent invasive disease among household contacts of index
patient.
ITu032I The prevalance of serum nv among hemodialysis
patients
T. Akpolat, M. Gunaydin, A. Pekbay, M. Cetin, C. Eroglu, E. Guner
Ondokuz Mayis University, School ofMedicine, Samsun, Turkey
Objective: A possible agent for human non-A-G hepatitis has been reported
:md named transfusion transmilled virus (TTV). The aim of this study is to
evaluate the prevalence ofserum TTV-DNA among hemodialysis patients
and the possible correlations ofserum TTY-ONA with antibody to hepatitis
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C IIirus (Anti-HCY), chronic liver dysfunction, number of blood transfu-
sions, serum hepatitis B surface antigen (HBs Ag), duration of hemodialysis
therapy, history of renal transplantation and patients' age and sex.
Methods: 40 hemodialysis patients and 26 healthy controls were included in
the study. lTV-DNA was detected by using a semi-nested PCR with
primers which Rank an 286-bp and 277 bp in a conserved region ofthe ITV
genome.
Results: 19 of 40 hemodialysis patients (48%) had positive serum TTV-
DNA and this was higher than in healthy controls. The prevalance of Anti-
HCV was higher and mean duration ofhemodialysis therapy was longer in
lTV-negative patients than in lTV-positive patients.
There was no significant difference between the ITV-DNA positive and
negative groups regarding, number of blood transfusions, serum HBs Ag,
chronic liver dysfunction, history of renal transplantation and patients' age
and sex.
Conclusion: Hemodialysis patients carry the risk for ITV infection and
transmission routes and clinical significance of TTV infection in these
patients remain to be defined.
[Tu0331 Enterotoxigenic Bacteroicl@s fragi/is (ETBF) and
diarrhoea
G. Zhang, A. Ramz-Rida, A. Weintraub
Karolinska Institute, Huddinge Unillersity Hospital, Stockholm, Sweden
Objective: To analyse the association between enterotoxigenic Bacteroides
fragilis (ETBF) and diarrhoeal disease.
Methods: lmmunomagnetic separation and PCR assay (IMS-PCR), based
on the use of B. fragilis monoclonal antibodies (mAb C3 and 4H8), was
employed to detect ETBF from clinical samples.
Results: A total of922 faecal samples were analysed, including 728 samples
from patients with diarrhoea and 194 samples from controls. ETBF was
detected in 195 of 728 (26.8%) of the patients with diarrhoea and in 24
(12.4%) ofthe healthy controls. The difference between the two groups was
significant (p < 0.01). ETBF was also found as the only potential diarrhoeal
pathogen in 91 out of728 (12.5%) patients.
The distribution of ETBF among the B. fragilis strains showed that the
patients harbouring ETBF, a majority (54%) of B. fragilis isolates were
identified as ETBF. Only 32% ofthe B. fragilis strains isolated from controls
were enterotoxin positive. In about 90% of the patients the ETBF strains
dominate among B. fragilis isolates. The corresponding figure for the
controls was 12%. There was a significant difference in individual percen-
tages of ETBF among isolated B. fragilis strains between patients and
controls.
Conduslons: High carriage ofETBF in patients with diarrhoea indicates an
associated with the disease. The higher counts of ETBF in the patients as
compared with asymptomatic carriers may result in higher concentration of
enterotoxin production.
ITu034IMicrobiological surveillance of diphtheria in Eastern
Europe
R. S. Kozlov', A. Efstratiou2, K. H. Engler2
Partners of the European Commission DGXII INCa Copernicus programme
IC15 CT.98.0302; 'Institute ofAntimicrobial Chemotherapy, Smolensk,
Russian Federation; 2pHLS Central Public Health Laboratory, London, United
Kingdom
Objectives: Within the remit of the European Commission DGXlI INCa
Copernicus programme IC15 CT.98.0302 (1998-2001); to improve the
microbiological surveillance of potentially toxigenic corynebacteria, to
organise a network of Reference Laboratories within Eastern Europe and
to stimulate information and technology exchange between countries of
Eastern and Western Europe.
Methods: The establishment ofa pan European network between partners
provides the basis of our European Commission INCa Copernicus pro-
gramme IC15 CT.98.0302. The successful collaboration of partners within
this programme and harmonised interaction with countries participating
within the ongoing European Commission DGXlI BioMed2 programme,
along with specific research activities, has led to formation of an effective
microbiological network for diphtheria. The newly established international
quality assurance programme is essential for improvements in microbiolo-
gical surveillance and standardisation oflaboratory methodologies.
Results: The formation of Diphtheria Reference Centres within panner
countries has enabled field evaluation studies and implementation of
specialised diagnostic methods (e.g. PCR, ribotyping). The creation of a
surveillance database, rapid information exchange and the monitoring of
new and existing clones ofthe causative organism Corynebacterium diphtheriae
have contributed towards improvements in diphtheria control.
Conduslons: This project can be used as an example ofsuccessful collabora-
tion between countries ofEastern and Western Europe, leading to improve-
ments in laboratory diagnosis, strengthening of surveillance and
identification of 'potentially epidemic' strains of a re-emerging infectious
disease. As the epidemic in Europe declines, it is crucial to have in place, a
reliable monitoring system, so as to determine the importance of non-
toxigenic, tox-gene-bearing corynebacteria and to sustain a high level of
awareness amongst clinicians and microbiologists.
P:14/1 - Surveillance of infectious diseases and antibiotic
resistance - I
IMoP266I European antimicrobial resistance surveillance
system: Stn!ptoeo«uS pneumoniae susceptibility test results
I. K. Veldhuijzen" S. L. A. M. Bronzwaer',J. Degener2,J. Kool'
EARSS participants; 'National Institute ofPublic health and the Environment,
Bilthollen; 2Academic Hospital Groningen, Groningen, Netherlands
Background: The European Antimicrobial Resistance Surveillance System
(EARSS) is a network of national surveillance systems. Susceptibility test
results of Streptococcus pneumoniae in blood- and CSF isolates are being
collected since the last quarter of 1998.
Methods: Patient- and isolate information is collected through Isolate
Record Forms that have been developed to enable standardised data
processing. The laboratories interpret the test results according to national
guidelines. The national coordinators collect resistance data from the
different laboratories and send it in EARSS data exchange format (ASCII)
to the central database quarterly. Susceptibility test results from 165 labs
from 11 European countries were analysed. The proportion ofoxacillin (=
penicillin) resistant Streptococcus pneumoniae (PRSP) was calculated.
Results: The proportion of PRSP did not exceed 5% in Finland (8/213),
Germany (4/150), Iceland (1/27), The Netherlands (8/352), and Sweden (25/
1081). The proportion ofPRSP in the UK was 8% (19/240), Italy 14% (If
52), Portugal 14% (5/37), Ireland 21 % (23/110), Luxembourg 22% (219),
and Greece 52% (13/25), respectively.
Condusion: These data show a north-south gradient in the proportion of
invasive PRSP across Europe. In the northern European countries PRSP are
not very prevalent, while southern European countries and Ireland report
proportions ranging from 14 to 52%. EARSS will continue to monitor
resistance in the EU, extending the set ofpathogens under surveillance in the
near future.
IMoP267I European antimicrobial resistance surveillance
system: Staphylococcus aureus susceptibility test results
I. K. Veldhuijzen', S. L. A. M. Bronzwaer',J. Degener2,J. Kool'
EARSS participants; 'National Inslitute ofPublic health and the Enllironment,
Bilthollen; 2Academic Hospital Groningen, Groningen, Netherlands
Background: The European Antimicrobial Resistance Surveillance System
(EARSS) is a network of national surveillance systems. Susceptibility test
results of Staphylococcus aureus in blood isolates are being collected since the
last quarter of 1998.
Methods: Patient- and isolate information is collected through Isolate
Record Forms that have been developed to enable standardised data
processing. The laboratories interpret the test results according to national
guidelines. The national coordinators collect resistance data from the
different laboratories and send it in EARSS data exchange format (ASCII)
to the central database quarterly. Susceptibility test results from 160 labs
from 11 European countries were analysed. The proportion ofoxacillin ( =
methicillin) resistant Staphylococcus aureus (MRSA) was calculated.
Results: The proportion ofMRSA did not exceed 5% in Denmark (0/502),
Finland (9/250), Iceland (0/21), the Netherlands (1/495) and Sweden (24/
1615). The proportion of MRSA for Germany was 7% (24/331), Luxem-
bourg 13% (5/40), Greece 36% (15/42), Italy 41 % (279/687), Ireland 42%
(127/306), and Portugal 57% (47/83), respectively.
Conduslon: These data show a wide variation in the proportion ofinvasive
MRSA across Europe. In the northern European countries MRSA is seldom
